IKT News and Press, Inhibikase Therapeutics Inc. From 04/21/22

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference PR Newswire BOSTON and AT...

Inhibikase Therapeutics Inc. (NASDAQ:IKT) traded at a new 52-week high today of $11.80. This new high was reached on above average trading volume as 11.5 million shares traded hands, while the average 30-day volume is approximately 94,000 shares. Inhibikase Therapeutics Inc is a clinical...

Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 PR Newswire BOSTON and ATLANTA , April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company de...

Inhibikase Therapeutics, Inc. (IKT) Q4 2021 Results Conference Call April 1, 2022 08:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Dr. Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Presentation Operator Greetings, welcome to Inhi...

Inhibikase Therapeutics press release (NASDAQ:IKT): FY GAAP EPS of -$0.81. Revenue of $3.1M (+342.9% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.81, revenue of $3.1M

Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stag...

Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit PR Newswire BOSTON and ATLANTA , March 28, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compan...

Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 PR Newswire BOSTON and ATLANTA , Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing t...

Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference PR Newswire BOSTON and ATLANTA , March 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...

Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference...